These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Sweet complexity: Børud B; Koomey M Front Cell Infect Microbiol; 2024; 14():1407863. PubMed ID: 38808060 [TBL] [Abstract][Full Text] [Related]
5. Genetic, structural, and antigenic analyses of glycan diversity in the O-linked protein glycosylation systems of human Neisseria species. Børud B; Aas FE; Vik A; Winther-Larsen HC; Egge-Jacobsen W; Koomey M J Bacteriol; 2010 Jun; 192(11):2816-29. PubMed ID: 20363948 [TBL] [Abstract][Full Text] [Related]
6. Characterization of a Unique Tetrasaccharide and Distinct Glycoproteome in the O-Linked Protein Glycosylation System of Neisseria elongata subsp. glycolytica. Anonsen JH; Vik Å; Børud B; Viburiene R; Aas FE; Kidd SW; Aspholm M; Koomey M J Bacteriol; 2016 Jan; 198(2):256-67. PubMed ID: 26483525 [TBL] [Abstract][Full Text] [Related]
7. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005. Harrison LH; Shutt KA; Schmink SE; Marsh JW; Harcourt BH; Wang X; Whitney AM; Stephens DS; Cohn AA; Messonnier NE; Mayer LW J Infect Dis; 2010 Apr; 201(8):1208-24. PubMed ID: 20199241 [TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in pilin glycosylation Locus of Neisseria meningitidis expressing class II pili. Kahler CM; Martin LE; Tzeng YL; Miller YK; Sharkey K; Stephens DS; Davies JK Infect Immun; 2001 Jun; 69(6):3597-604. PubMed ID: 11349019 [TBL] [Abstract][Full Text] [Related]
9. Genetic characterization of pilin glycosylation and phase variation in Neisseria meningitidis. Power PM; Roddam LF; Rutter K; Fitzpatrick SZ; Srikhanta YN; Jennings MP Mol Microbiol; 2003 Aug; 49(3):833-47. PubMed ID: 12864863 [TBL] [Abstract][Full Text] [Related]
10. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine. Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X mBio; 2019 Sep; 10(5):. PubMed ID: 31506309 [TBL] [Abstract][Full Text] [Related]
11. Genetic determinants of genus-level glycan diversity in a bacterial protein glycosylation system. Hadjineophytou C; Anonsen JH; Wang N; Ma KC; Viburiene R; Vik Å; Harrison OB; Maiden MCJ; Grad YH; Koomey M PLoS Genet; 2019 Dec; 15(12):e1008532. PubMed ID: 31869330 [TBL] [Abstract][Full Text] [Related]
12. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Biolchi A; De Angelis G; Moschioni M; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Comanducci M; Budroni S; Giuliani MM; Rappuoli R; Pizza M; Boucher P Vaccine; 2020 Nov; 38(47):7542-7550. PubMed ID: 33036804 [TBL] [Abstract][Full Text] [Related]
14. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease. Harris SL; Zhu D; Murphy E; McNeil LK; Wang X; Mayer LW; Harrison LH; Jansen KU; Anderson AS Hum Vaccin; 2011; 7 Suppl(Suppl):68-74. PubMed ID: 21245657 [TBL] [Abstract][Full Text] [Related]
15. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218 [No Abstract] [Full Text] [Related]
16. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380 [TBL] [Abstract][Full Text] [Related]
17. Whole genome typing of the recently emerged Canadian serogroup W Neisseria meningitidis sequence type 11 clonal complex isolates associated with invasive meningococcal disease. Tsang RSW; Ahmad T; Tyler S; Lefebvre B; Deeks SL; Gilca R; Hoang L; Tyrrell G; Van Caeseele P; Van Domselaar G; Jamieson FB Int J Infect Dis; 2018 Apr; 69():55-62. PubMed ID: 29414677 [TBL] [Abstract][Full Text] [Related]
18. Genetic and molecular analyses reveal an evolutionary trajectory for glycan synthesis in a bacterial protein glycosylation system. Børud B; Viburiene R; Hartley MD; Paulsen BS; Egge-Jacobsen W; Imperiali B; Koomey M Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9643-8. PubMed ID: 21606362 [TBL] [Abstract][Full Text] [Related]
19. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. Pajon R; Fergus AM; Koeberling O; Caugant DA; Granoff DM PLoS Negl Trop Dis; 2011 Sep; 5(9):e1302. PubMed ID: 21909444 [TBL] [Abstract][Full Text] [Related]
20. A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model. Mountzouros KT; Belanger KA; Howell AP; Bixler GS; Madore DV Infect Immun; 2002 Dec; 70(12):6576-82. PubMed ID: 12438327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]